Mantle cell lymphoma (MCL) predominantly affects older adults, with a median age at diagnosis of 70 years. A frequently aggressive yet incurable lymphoma, the goal of therapy for MCL is to turn a potentially life-threatening illness into a chronic disease with prolonged periods of remission. Larg...
Mantle cell lymphoma is an aggressive non-Hodgkin’s lymphoma that remains incurable with current chemotherapeutic approaches. Despite response rates to many regimens of 50% to 70%, the disease typically progresses after chemotherapy with a median survival time of approximately 3 years. There is no ...
Mantle cell lymphoma doi:10.1007/s11864-000-0041-xCurrent Treatment Options in OncologyDensmore, J JWilliams, M E
Mantle Cell Lymphoma-Lymphomatous Intestinal Polyposis: 429Mohamadameen, Ranje RJLe, BruceO'Leary, DennisSobrado, JavierOfficial journal of the American College of Gastroenterology | ACG
Mantle cell lymphoma is a rare form of B-cell non-Hodgkin lymphoma. It is a type of blood cancer that affects white blood cells called lymphocytes.
Healio spoke to experts in mantle cell lymphoma to discuss the latest developments in the study and treatment of the condition, new treatments coming down the pipeline, challenges in the field and more.
MCL兼具侵袭性淋巴瘤进展迅速和惰性淋巴瘤不可治愈的双重特点,大多数有很强侵袭性,难以治愈,不同治疗方案的中位生存期约3-5年。近年来的临床研究显示,套细胞淋巴瘤也是一组异质性肿瘤,预后差异很大。2022新版WHO淋巴造血肿瘤分类中明确提出了套细胞淋巴...
套细胞淋巴瘤(mantle cell lymphoma, MCL)是一种不常见的血液系统恶性肿瘤,占非霍奇金淋巴瘤7%。其特征是t(11;14)(q13;q32)移位,导致过度表达细胞周期素D1。绝大多数病例的免疫组化染色可以发现Cyclin D1和CD5阳性。少部分Cyclin D1阴性的患者常有SOX-11表达阳性。套细胞淋巴瘤仍然是一群异质性很强的疾病,...
Figure 2. Identification of patients with mantle cell lymphoma (MCL) treated with at least 1 line of therapy for the analysis of treatment patterns. 1L = first-line; 2L = second-line; ICD-9 CM/ICD-10 CM = International Classification of Disease, Ninth/Tenth Revision—Clinical Modification. ...
This case describes a 56-year-old Caucasian man with a newly diagnosed mantle cell lymphoma (MCL) and multiple endocrine neoplasia type 2 (MEN-2) diagnosed at the age of 20years. His MEN-2 presented as a medullary thyroid carcinoma. The patient was previously treated with a thyroidectomy and...